Glial activation and neuroinflammation contribute to pathogenesis of neurodegenerative diseases, linked to neuron loss and dysfunction. α-Synuclein (α-syn), as a metabolite of neuron, can induce microglia activation to trigger innate immune response. However, whether α-syn, as well as its mutants (A53T, A30P, and E46K), induces astrocyte activation and inflammatory response is not fully elucidated. In this study, we used A53T mutant and wild-type α-syns to stimulate primary astrocytes in dose-and time-dependent manners (0.5, 2, 8, and 20 μg/ml for 24 hr or 3, 12, 24, and 48 hr at 2 μg/ml), and evaluated activation of several canonical inflammatory pathway components. The results showed that A53T mutant or wild-type α-syn significantly upregulated mRNA expression of toll-like receptor (TLR)2, TLR3, nuclear factor-κB and interleukin (IL)-1β, displaying a pattern of positive dose-effect correlation or negative time-effect correlation. Such upregulation was confirmed at protein levels of TLR2 (at 20 μg/ml), TLR3 (at most doses), and IL-1β (at 3 hr) by western blotting. Blockage of TLR2 other than TLR4 inhibited TLR3 and IL-1β mRNA expressions. By contrast, interferon (IFN)-γ was significantly downregulated at mRNA, protein, and protein release levels, especially at high concentrations of α-syns or early time-points. These findings indicate that α-syn was a TLRs-mediated immunogenic agent (A53T mutant stronger than wild-type α-syn). The stimulation patterns suggest that persistent release and accumulation of α-syn is required for the maintenance of innate immunity activation, and IFN-γ expression inhibition by α-syn suggests a novel immune molecule interaction mechanism underlying pathogenesis of neurodegenerative diseases.
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| INTRODUCTION
Alpha-synuclein (α-syn) is a 140-amino acid protein highly enriched in presynaptic neuronal terminals and exerts multiple physiological functions such as synaptic vesicle turnover, synaptic plasticity, and molecular chaperone (Mori, Tanji, Yoshimoto, Takahashi, & Wakabayashi, 2002; Norris, Giasson, & Lee, 2004) , whereas its various dysfunctions are strongly implicated in pathogenesis of neurodegenerative diseases or synucleinopathies such as Parkinson's disease (PD), Alzheimer's disease (AD), and multiple system atrophy (MSA) (Goedert, 2001; Norris et al., 2004) . Extensive studies have shown that α-syn serves as a major component of cytoplasmic inclusions such as Lewy bodies/neurites, liposomes, and exosomes to trigger intracellular apoptotic mechanism underlying neuronal damage (Lanzillotta et al., 2015; Majd, Power, & Grantham, 2015) . However, fewer studies show that α-syn functions as antigenic stimulator of glial activation and innate immunity to initiate extracellular inflammatory mechanism by its release from neurons and contribute to neurotoxic pathogenesis (Lee et al., 2010; Ma et al., 2013; Rivest, 2009) . A hallmark of this neurotoxicity is derived from conversion of α-syn from constituent soluble monomers to aggregated amyloid-like insoluble forms, as well as formation of other pathologic forms such as missense mutations (A53T, A30P, and E46K) and multiple copies of wild-type (WT) α-syn (Eschbach & Danzer, 2014; Goedert, 2001) . These molecular changes and high expression of α-syn are persistently observed in substantia nigra of familial or sporadic PD, showing a positive association of α-syn with PD: genetic mutation of α-syn causes familial PD with early-onset and more severe pathogenesis, and multiplication of normal WT form increases risk of sporadic PD (Croisier, Moran, Dexter, Pearce, & Graeber, 2005; Nishioka et al., 2006) .
In a traditional manner, α-syn is an exclusively intracellular acidic protein and largely located within neurons in substantia nigra, neocortex, and hippocampus (Kim, Seo, & Suh, 2004) . Also, α-syn can be expressed in astrocytes (Tanji et al., 2001) , oligodendroglia (Mori et al., 2002) , and peripheral immune cells such as T cells, B cells, natural killer cells, and monocytes (Shin et al., 2000) , and be secreted or released into biological fluids such as cerebrospinal fluid and blood plasma (Lee et al., 2006; Sui, Bullock, Erickson, Zhang, & Banks, 2014) . In addition, α-syn can be transferred to neighboring astrocytes or neurons to promote formation of inclusion bodies, leading to inflammatory responses and neuron death (Desplats et al., 2009; Lee et al., 2010) . This widespread cell expression and release of α-syn provides multiple potential stimulatory sources responsible for glial activation and innate immunity (Rivest, 2009) . While microglia are known as a resident immune cell in the brain to contribute to synucleinopathies, astrocytes are also found to express toll-like receptors (TLRs) and release proinflammatory cytokines and participate in α-syn-induced neuroinflammation (Farina, Aloisi, & Meinl, 2007) . Therefore, α-syn plays a critical role in the etiology of synucleinologies: its closer relevance to innate and adaptive immune systems and its multisystematic involvement in the pathogenesis of synucleinologies.
Substantial evidence supports the central role of immune system in the pathogenesis of PD. In human postmortem tissues and animal models of PD, abnormal α-syn expression is always accompanied by inflammation and immune responses including activated astrocytes and microglia, increased proinflammatory cytokines, infiltration of CD4 lymphocytes, MHCII expression, and IgG deposition (Brochard et al., 2009; Harms et al., 2013; Hirsch & Hunot, 2009 ). This inflammatory process involves at least four components of canonical inflammatory pathway (González-Reyes, NavaMesa, Vargas-Sánchez, Ariza-Salamanca, & Mora-Muñoz, 2017): (a) the endogenous or exogenous stimulators, including microbial factors such as pathogen-associated molecular patterns (PAMPs), nonmicrobial factors such as toxic compounds, self-debris or damage-associated molecular patterns (DAMPs) (Béraud et al., 2011) , and senescence-associated secretory phenotype (SASP) derived from tissue injury/ malfunction and cell apoptosis/necroptosis (Pasparakis & Vandenabeele, 2015) ; (b) the receptors such as TLRs and cytokine receptors to recognize molecule alteration in extracellular microenvironment (Roodveldt et al., 2013) ; (c) the downstream mediators such as nuclear factor (NF)-κB to crosstalk with other stimulators or signal pathways and impact inflammatory outcomes; and (d) the effectors such as cytokines, vasoactive substances, complement components, and proteolytic enzymes released from immune cells (e.g., macrophages) and tissue cells, determining neurotoxicity and cell fate. In this study, A53T mutant or WT α-syn was used as an antigenic stimulator to induce activation of canonical inflammatory pathway involving TLRs 1, 2, 3, and 4, NF-κB and cytokines such as interleukin (IL)-1β, interferon (IFN)-γ, IFN-β, and tumor necrosis factor (TNF)-α.
Taken together, α-syn, as an abnormal metabolite of neurons, is released into extracellular space and induces activation of glial cells and inflammatory response, reflecting its immunogenic attribution (Lee, Bae, & Lee, 2014; Roodveldt et al., 2013; Sanchez-Guajardo, Barnum, Tansey, & RomeroRamos, 2013) . However, correlation between α-syn stimulation and neurotoxic outcomes in astrocytes remains to be fully elucidated, especially in its dose and temporal stimulation patterns. In this study, we utilized A53T mutant or WT α-syn to stimulate astrocytes in dose-and time-dependent manners and systematically evaluated activation pattern of innate immunity and inflammatory outcomes by expression profiles of inflammatory pathway components (TLRs 1-4, NF-κB, TNF-α, IL-1β, IFN-γ, and IFN-β) and use of TLR antagonists. Our findings provide a novel insight into the neurotoxic feature of α-syn and inflammatory mechanism underlying pathogenesis of synucleinopathies.
| MATERIALS AND METHODS

| Experimental design
Our aim is to determine α-syn-induced activation pattern of canonical inflammatory pathway and neurotoxic outcomes. In experimental design, we gave the following considerations: (a) Choice of stimulator α-syns. A53T mutant α-syn is neurotoxic in familial PD, but no conclusive evidence shows that WT α-syn has a neurotoxic role in astrocyte-mediated neuroinflammation, although high amount of α-syn can selfassemble and trigger protein aggregation, a PD-inducing factor (Eschbach & Danzer, 2014) . Thus, we mainly evaluated the neurotoxicity of A53T mutant α-syn, with WT α-syn as a control to compare their possible difference in stimulation effect; (b) Doses and time-points of stimulation. The varied physiological concentrations of α-syn in blood and CFS are detected at nanogram/milliliter level (Koehler et al., 2015; Lin et al., 2017) , which are up to tenfold in serum and plasma and up to 10,000-fold higher in whole blood due to its abundant expression in hematopoietic system (Mollenhauer et al., 2011 (Mollenhauer et al., , 2012 . Previous studies in vitro show a range of concentrations of α-syn available from 0.1 to 10 μg/ml at one time-point (24 hr) (Roodveldt et al., 2010 (Roodveldt et al., , 2013 . In this study, we used four concentrations of 0.5, 2, 8, 20 μg/ ml with a fixed time-point 24 hr and four time-points of 3, 12, 24, 48, or 72 hr with a fixed concentration of 2 μg/ml, to sufficiently show dose and temporal stimulation effects; (c) Choice of 90% cell confluency. α-Syn stimulation was not observed to effectively inhibit cell growth, and overgrowth (100%) of the cells gave rise to plenty of floating or dead cells, which may potentially interfere with the sensitive detection by qRT-PCR; (d) Determination of inflammatory pathway components. TLRs are the well-established receptors of innate immunity, and TLR2 or TLR3 is a representative of cell surface receptors and intracellular receptors, respectively. TLR3 activation by α-syn is likely attributed to endocytosis of α-syn as evidenced previously. TLR1 and TLR4 were also detected for supporting purpose. NF-κB is a core regulator of canonical inflammatory pathway that is known to crosstalk with many other bioactive factors. IL-1β, TNF-α, and IFN-γ are common effectors of inflammatory outcomes, and in this study, we focused on expression profile of IL-1β as a representative of cytokines, although a similar induction pattern of TNF-α was also observed; and (e) Data normalization. 
| Astrocyte isolation and cell culture
According to an established protocol (Gorina, Font-Nieves, Márquez-Kisinousky, Santalucia, & Planas, 2011; Han, Wang, Zhou, & Ransohoff, 2000) , mixed glial cells were prepared from 80 cerebral cortices of new-born (3-4 days) C57BL/6 mouse pups with hypothermia (on ice 20 min)
anesthesia, and astrocytes were separated by differential adhesion of cell types according to previously described method. In brief, cerebral cortex was removed from brain and homogenized into single-cell suspension by mincing, trypsinizing, and passaging through nylon mesh. Primary glial cells were washed and cultured for 16 hr in poly-D-lysine-coated 75-cm 2 flasks (4 pups/flask) with complete DMEM/F12 containing 10% FBS (heat-inactivated), 100 U/ml penicillin, and 100 μg/ml streptomycin in a humidified 5% CO 2 , 95% air atmosphere at 37°C. After 16-hr incubation, horizontal shakes by hands and washes with HBSS were performed to remove oligodendrocytes and microglia, and astrocytes were adhered for further culture. Purity of astrocytes was determined by immunostaining for GFAP (a specific marker for astrocytes) and immunofluorescence microscopy. All astrocytes were cultured for a total of 7-10 days and then shaken and washed again before they were detached from plates by trypsinization (0.05% Trypsin-EDTA), resuspended, and plated in complete DMEM-F12 medium for planned experiments.
| Immunofluorescence microscopy
Astrocytes were seeded and cultured on coverslips until confluent and fixed in ice-cold solution of methanol and acetone (1:1) for 5 min. After they were rinsed twice in phosphatebuffered saline (PBS, pH 7.4), the main steps below were performed with PBS washes of 10-15 min in between: (a) Glycine (2.25%, 20 min) was put to remove endogenous fluorescent; (b) blocker buffer containing 1% bovine serum albumin (BSA), 0.3% Triton X-100, and 10% goat serum in PBS was made for blocking nonspecific staining at room temperature for 1 hr; (c) primary antibody for GFAP (rabbit anti-mouse, 1:1,000) and IgG from rabbit serum (negative control) were used at 4°C overnight; (d) Alexa Fluor ® 514
fluorescein-conjugated goat anti-rabbit antibody (1:1,000) was added at room temperature for 1 hr; (e) DAPI was used for nuclear and chromosome counterstaining at 1 μg/ ml for 10 min. After final wash in PBS, coverslips were mounted with Fluoromount ™ Aqueous Mounting Medium and examined under fluorescence microscope (Nikon Model: ECLIPSE Ni-U, Tokyo, Japan).
| Astrocyte treatment
Astrocytes were divided into multiple treatment groups in 6-well plates and cultured to about 90% confluency. Culture medium was replaced with fresh complete DMEM/F12 containing appropriate final concentration of individual drugs or their combinations (Mollenhauer et al., 2011 (Mollenhauer et al., , 2012 . For dose dependency, WT α-syn or A53T mutant was set at 0.5, 2, 8, 20 μg/ml for a fixed time-point (24 hr); For time dependency, time-points were set at 3, 12, 24, 48 hr at a fixed concentration (2 μg/ml) of α-syn; for combination treatment, α-syn (2 μg/ml) and CPT22 (5 μg/ml) or C34 (5 μg/ml) coincubated for a fixed time 24 hr. These treatment groups and control groups were cultured in a humidified 5% CO 2 , 95% air atmosphere at 37°C for 24 hr unless otherwise indicated. Supernatants from each group were collected and stored at −80°C, and astrocytes were harvested with TRIzol Reagent (0.5 ml/well) or lysis buffer (0.2 ml/well) and properly stored according to instructions on qRT-PCR or western blotting analysis.
| Determination of TLRs and cytokine gene expression
Expression of genes for TLRs 1-4, NF-κB, IL-1β, IFN-γ, IFN-β, and glyceraldehyde phosphate dehydrogenase (GAPDH, an internal control) was determined using two-step qRT-PCR method. . All qRT-PCR products were run in duplicates and their average values were used in data analysis.
| Western blotting
Protein expression of TLRs 2 and 3, IL-1β, and IFN-γ was determined by western blotting with β-actin as internal control. In brief, astrocytes (1 × 10 6 cells/well) treated in a 6-well plate were washed once with ice-cold PBS and lysed in lysis buffer supplemented with complete protease inhibitor cocktail and 1 mM phenylmethanesulfonyl fluoride (PMSF, before use). Cell debris was removed by centrifugation at 13,000 g, 4°C for 30 min, and protein concentration was determined by Bradford reagent (Bio-Rad). A total of 30 μg lysate protein for one lane was added to appropriate denaturing sample buffer and heated at 95°C for 5 min and then was resolved by Mini-PROTEIN TGX Precast Gels from Bio-Rad and transferred to 0.45 μm polyvinylidenedifluoride (PVDF) membrane (Millipore, USA) using Bio-Rad Trans-Blot SemiDry Transfer Cell and System. After blocked in 5% milk at room temperature for 1 hr, the membrane was probed with appropriately diluted primary antibodies (TLR2 and TLR 3 at 1:300; IL-1β and IFN-γ at 1:800, β-actin at 1:2,000) in 5% milk at 4°C overnight and then hybridized with appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (1:2,000) at room temperature for 1 hr. Results were visualized using Enhanced Chemiluminescence (ECL) Substrate Kit (Bio-Rad), and films were exposed and developed in dark room according to manufacturer's instructions.
To confirm equal loading of proteins in each lane, membrane was re-probed for β-actin following removal of background bands by incubation at 37°C for 30 min with Gentle Review™ Stripping Buffer (Amresco-inc, Solon, USA).
| Cytokine release measurements
Supernatants collected from each group were centrifuged at 300 g at 4°C for 10 min and then stored at −80°C or used for measurement of cytokine release. IFN-γ was chosen as a typical representative of proinflammatory cytokines to assess neurotoxicity in astrocytes. IFN-γ protein levels in each supernatant were measured using specific sandwich ELISA kits according to manufacturer's instruction, and the normalized concentrations were automatically generated through 460 nm filter plus 570 nm subtraction on Microplate Reader (Bio-Rad).
| Data analysis
Data are expressed as means ± standard deviation and scatter charts, displaying sample distribution, sample number (n), means (-) . Dose-and time-dependent effects of single drugs were evaluated statistically by one-way randomized blocks ANOVA, in combination with Fisher's least significant differences (LSD), for comparison of different treatment levels, whereas paired comparison between one and combined treatments at each level was performed by two-way ANOVA methods combined with Margin Means. Normality and homogeneity of variance were examined by Shapiro-Wilk test and Levene test at a 0.05 significance level, respectively. When either assumption was significant, statistical analysis was performed on suitably transformed data. In addition, release levels (IFN-γ) by ELISA are statistically presented as concentration values, and protein levels (TLR2, TLR3, IL-1β, and IFN-γ) are statistically presented as grayscales from densitometry (ImageJ software). All statistical analyses were conducted using SAS software (SAS 9.1.3; SAS Institute Inc., Cary, NC, USA), and statistically significant differences were defined as p < 0.05, with p values labeled in figures.
| RESULTS
| Identification of primary astrocytes
Glial fibrillary acidic protein is an intermediate filament specifically expressed in astrocytes, and immunofluorescence microscopy showed that the GFAP-positive astrocytes comprised a heterogeneous population: small-, medium-, and large-sized cells with multiple primary and secondary branches that generally extend to outer space in a long distance ( Figure 1a ). This morphological characteristic may reflect multiple cell division phases of astrocytes, which is different from the appearance of microglia (1-2 very short branches). Purity of astrocytes was determined by calculating the proportion of GFAP-positive cells in total numerated cells (DAPI-positive nuclei staining) within five randomly selected areas under microscope, showing that approximately 94% (93.96 ± 4.03%) of DAPI-positive cells were GFAPpositive. Meanwhile, IgG from rabbit serum, the equivalent to GFAP antibody, was used as negative control for the immunostaining procedure and microscope indices, and no GFAP-positive cells were observed (Figure 1b ).
| α-Syn-induced activation of TLRs 1, 2, 3, and 4 and NF-κB in astrocytes
Toll-like receptors are a group of type I transmembrane glycoprotein, responsible for activation of innate immunity by recognizing foreign pathogens such as PAMPs or endogenous antigens such as cell debris, DAMPs, and SASP. In the thirteen TLR functional components detected so far, TLRs 1, 2, 4, 5, and 6 are expressed on cell surface for extracellular recognition and TLRs 3, 7, 8, and 9 are localized on endosomes or lysosomes for detecting intracellular molecules such as viral or bacterial nucleic acids. In this study, TLR2, TLR3, and NF-κB, three components of canonical inflammatory pathway, were determined following stimulation of A53T mutant or WT α-syn, with TLR1 and TLR4 detection only for the supporting purpose.
In dose-dependent stimulation, A53T mutant and WT α-syns increasingly upregulated mRNA expression of TLR2 and TLR3 with dose increase, displaying a induction pattern of positive dose-effect correlation (PDEC) (Figure 1c,d) . The (Figure 1g ), which is a similar pattern to its mRNA expression. Together, A53T mutant and WT α-syns can activate expression of TLR2 and TLR3 at both mRNA and protein levels, with A53T mutant having more activation effect than WT α-syn.
Nuclear factor-kappa B, as a core regulator in inflammatory signal pathway, has a widespread molecular connection with its upstream molecules such as TLRs, its downstream effectors cytokines, and other signal pathways. Stimulation of A53T mutant moderately upregulated NF-κB mRNA expression with a significant difference between high-dose (8, 20 μg/ml) and low-dose (0.5, 2 μg/ ml) groups or between early (3, 12 hr) and later (24, 48 hr) time-point groups (Figure 2a ). The significant difference at ΔΔCt (p < 0.05) between treatment groups was statistically shown as (Figure 2a ): A53T-2 (−0.49 ± 0.394, n = 8) versus A53T-8 (−1.263 ± 0.376, n = 4) at p = 0.0117; A53T 12 hr (−1.288 ± 0.354, n = 4) versus A53T 24 hr (−0.49 ± 0.394, n = 8) at p = 0.0107. This expression pattern was similar to those of TLR2 and TLR3, reflecting participation of NF-κB in α-syn-induced inflammatory signal pathway. By contrast, WT α-syn upregulated NF-κB expression only at early time-points (3 and 12 hr) (WT 12 hr (−1.043 ± 0.266, n = 4) versus WT 24 hr (−0.553 ± 0.109, n = 4) at p = 0.0461), which then declined later on, with no significant induction effect at 0.5-20 μg/ml WT α-syn (Figure 2a ). In addition, the induction amplitude by , and β-actin (45 kDa), a representative of three experiments. The signal size was identified according to manufacturer's instruction, and β-actin was used as reference control. (f, g) Densitometric analyses of western blotting (ImageJ software), indicating that TLR2 and TLR3 protein level (grayscales) were significantly enhanced at 20 μg/ml and at 0.5-20 μg/ml, respectively, compared to control level (p < 0.05). In time dependency, the maximal level of TLR3 was detected at 12-hr (p < 0.05 compared to 3-hr level or control level) and then declined to an appropriate level. The above data are presented by scatter charts showing sample distribution, sample number (n), means (-) and p values (significant difference specified at p < 0.05, by ANOVA, Margin means or LSD). Dose treatment at 2 μg/ml (24 hr) is the same condition as time treatment at 24 hr (2 μg/ml). TLR, toll-like receptor. [Colour figure can be viewed at wileyonlinelibrary.com] | WANG et Al.
A53T mutant was higher than WT α-syn at 8 and 20 μg/ ml (Figure 2a) , as statistically shown at ΔΔC t : WT-20 (−0.507 ± 0.102, n = 4) versus A53T-20 (−1.530 ± 0.154, n = 4) at p = 0.001.
| α-Syn-induced activation of cytokines in astrocytes
Cytokines, as effectors of inflammatory outcomes, contribute to a wide variety of neuroinflammatory disorders such as synucleinopathies, involving activation of glial cells and concomitant innate immune response. Expression and release of these cytokines is a pivotal immunological issue linked to neurotoxicity of extracellular space and neuronal injury. Accordingly, in this study, we determined α-syn-induced expression of cytokines IL-1β, IFN-γ, and IFN-β at mRNA or protein level in dose-and time-dependent manners.
Following stimulation of A53T mutant or WT α-syn, IL-1β mRNA expression was significantly upregulated in almost all treatment groups (Figure 3a) , displaying the typical induction patterns of PDEC and NTEC as evidenced in TLRs detection, and IFN-β expression was merely upregulated F I G U R E 2 The mRNA expression profiles of NF-κB, TLR1, and TLR4. (a) A53T mutant α-syn moderately upregulated NF-κB expression with a statistical significance (p < 0.05) between high-dose (8 and 20 μg/ml) and low-dose (0.5 and 2 μg/ml) groups or between early (3 and 12 hr) and later (24 and 48 hr) time-point groups. A53T mutant had a stronger induction effect than WT α-syn, displaying an induction tendency of positive dose-effect correlation or negative time-effect correlation. (b, c) TLR1 and TLR4 mRNA expressions were upregulated by A53T mutant α-syn, as shown with p values (p < 0.05) between treatment groups, displaying an induction tendency of positive dose-effect correlation. The above data are presented with scatter charts showing sample distribution, sample number (n), means (-) and p values (significant difference specified at p < 0.05, by ANOVA, Margin means or LSD). Dose treatment at 2 μg/ml (24 hr) is the same condition as time treatment at 24 hr (2 μg/ml). TLR, toll-like receptor. [Colour figure can be viewed at wileyonlinelibrary.com] by A53T mutant other than WT α-syn in most treatment groups (Figure 3b) , indicating involvement of IFN-β in A53T mutant α-syn-inducted astrocyte activation. The significant difference at ΔΔCt (p < 0.05) between dose treatment groups was statistically shown as: IL-1β (Figure 3a ): A53T 0.5 μg/ml (A53T-0.5) (−3.737 ± 0.534, n = 7) versus A53T-2 (−6.530 ± 0.903, n = 7) at p = 0.0269; A53T-2 (−6.530 ± 0.903, n = 7) versus A53T-8 (−8.698 ± 0.637, n = 5) at p = 0.0428; A53T-8 (−8.698 ± 0.637, n = 5) versus A53T-20 (−9.558 ± 0.354, n = 4) at p = 0.0394; WT-0.5 (−4.553 ± 0.463, n = 4) versus WT-2 (−7.135 ± 0.432, n = 4) at p = 0.0013; WT-2 (−7.151 ± 0.432, n = 4) versus WT-8 (−9.09 ± 0.438, n = 4) at p = 0.0381; IFN-β (Figure 3b ): A53T-0.5 (−0.9901 ± 0.243, n = 7) versus A53T-2 (−1.462 ± 0.267, n = 6) at p = 0.0483. Western blotting analysis (Figure 3e) showed that IL-1β protein level was reduced at 8 and 20 μg/ml in A53T mutant α-syn dose-related induction (Figure 3f ), an inconsistent induction pattern with PDEC at its mRNA level. The significant difference at grayscales (p < 0.05) between dose treatment groups was statistically shown as ( Figure 3f ): control (0.967 ± 0.127, n = 3) versus A53T-8 (0.454 ± 0.157, n = 3) at p = 0.0248; control (0.967 ± 0.127, n = 3) versus A53T-20 (0.421 ± 0.161, n = 3) at p = 0.0216. This abnormal phenomenon may be attributed to a potential exhaustive secretion or release of IL-1β under high-dose α-syn stimulation although no endotoxin or intrinsic toxicity of A53T mutant is detected by manufacturer. At timepoint of 3 hr, IL-1β level was obviously enhanced (control [0.967 ± 0.127, n = 3] versus A53T 3 hr [1.549 ± 0.194, n = 3] at p = 0.0429) and then declined later on, a consistent pattern with NTEC at its mRNA level (Figure 3f ), indicating that α-syn exerts a powerful stimulation action at early timepoints and subsequent exhaustive release may occur with time extension. Likewise, IFN-γ protein was detected at 19 kDa with a weak signal (Figure 3e) , showing that its protein levels were significantly reduced in almost all treatment groups compared to the control protein level, but at 48 hr, the protein level was somewhat reversed (Figure 3g ). The significant difference at grayscales (p < 0.05) between dose treatment groups was statistically shown as ( Figure 3g ): control (0.395 ± 0.0724, n = 3) versus A53T-2 (0.136 ± 0.057, n = 3) at p = 0.0358; control (0.395 ± 0.0724, n = 3) versus A53T-8 (0.146 ± 0.0472, n = 3) at p = 0.0403; control (0.395 ± 0.0724, n = 3) versus A53T 3 hr (0.117 ± 0.0442) at p = 0.0429. Furthermore, extracellular release profile of IFN-γ was detected by ELISA: Release level was significantly reduced at 20 μg/ml of A53T mutant or WT α-syn, or reduced at 3 and 12 hr by WT α-syn other than A53T mutant (Figure 3d) , indicating a specific correlation of IFN-γ release and WT α-syn induction. The significant difference at protein release (p < 0.05) between treatment groups was statistically shown as ( Figure 3d ): control (3.936 ± 1.961, n = 10) versus A53T-20 (0.4682 ± 1.457, n = 5) at p = 0.0376; control (3.936 ± 1.961, n = 10) versus WT-2 (2.104 ± 0.707, n = 4) at p = 0.0418; WT-2 (2.104 ± 0.707, n = 4) versus WT-20 (1.556 ± 0.354, n = 4) at p = 0.0474; WT 3 hr (0.713 ± 0.224, n = 4) versus A53T 3 hr (3.225 ± 0.994, n = 5) at p = 0.0464; WT 12 hr (1.458 ± 0.356) versus A53T 12 hr (2.547 ± 0.942) at p = 0.0417.
Together, A53T mutant or WT α-syn potentiated expressions of cytokines IL-1β and IFN-β at mRNA level to various degrees, generally showing two types of induction patterns, that is, PDEC and NTEC. However, high-dose A53T mutant α-syn reduced intracellular protein level of IL-1β, indicating a possible exhaustive effect by α-syn, and both A53T mutant and WT α-syns suppressed protein expression and release of IFN-γ as evidenced by qRT-PCR, western blotting, and ELISA, strongly indicating a possible negative correlation of α-syn with IFN-γ other than IFN-β in murine astrocyte activation.
| TLR2 blockage suppressed α-syninduced activation of innate immunity
To explore the role of TLRs in α-syn-induced activation of innate immunity, we chose TLR2 antagonist (CPT22, 5 μg/ ml) and TLR4 antagonist (C34, 5 μg/ml) to coincubate with A53T mutant α-syn (2 μg/ml) and then determined expression profiles of inflammatory pathway components. Additive application of CPT22 significantly downregulated mRNA expressions of TLR3 (Figure 4a ) and IL-1β (Figure 4e ), along with compensatory upregulation of TLR2 (Figure 4a ) or NF-κB expression (Figure 4c) , indicating an interaction existing between TLR2 and TLR3. By contrast, C34 had no significant effect on TLR2 or TLR3 expression (Figure 4b ) but upregulated NF-κB (Figure 4d ) and IL-1β (Figure 4f A53T 12 hr (−9.255 ± 0.586, n = 5) versus A53T/CPT22 12 hr (−6.615 ± 0.530, n = 4) at p = 0.006; A53T 24 hr (−6.538 ± 0.903, n = 7) versus A53T/CPT22 24 hr (−4.029 ± 1.189, n = 8) at p ≤ 0.0001; A53T 12 hr (−9.255 ± 0.586, n = 5) versus A53T/C34 12 hr (−10.145 ± 0.332, n = 4) at p = 0.0395. Taken together, blockage of TLR2 other than TLR4 suppressed α-syn-induced activation of innate immunity by downregulating TLR3 and IL-1β expressions, reflecting that TLR2 and TLR4 differently mediate α-syn-induced innate immunity, and TLR2 or TLR4 blockage does not inhibit NF-κB activity. However, the interaction mechanism of α-syn, TLRs and cytokines is complex and needs to be further investigated elsewhere.
| DISCUSSION
Despite much progress made in recent years, the underlying mechanism that α-syn triggers onset of several synucleinopathies such as AD, PD, and MSA remains to be fully elucidated. Chronic neuroinflammation and activated astrocyte and microglia are the common feature of these diseases (Harms et al., 2013; Rivest, 2009) , and dysfunctional α-syn, as an endogenous immunogenic substance or cell debris like DAMPs or SASP, may be a pivotal risk factor to exacerbate such a neuroinflammatory process (Barcia et al., 2012) . Among multiple isoforms of α-syn, A53T mutant α-syn is proven to be neurotoxic, but there is no enough evidence for WT α-syn neurotoxicity. In this study, we demonstrated that both A53T mutant and WT α-syns-induced astrocytemediated innate immune response, which is presented by activation of canonical inflammatory pathway components such as TLRs 1-4 and NF-κB and upregulated expression of IL-1β and IFN-β. However, IFN-γ, as an important effector or regulator cytokine in inflammatory response, was unexpectedly downregulated at its mRNA, protein, and protein release levels. Additive application of TLR2 antagonist (CPT22) partly inhibited α-syn-induced expressions of TLR3 and IL-1β, whereas TLR4 antagonist (C34) did not do so. These results suggest that α-syn is a TLRs-mediated powerful immunogenic agent and can activate canonical inflammatory signal pathway to regulate innate immunity, with A53T mutant having a stronger induction effect than WT α-syn.
Both astrocytes and microglia are the important players of immune activation and neuroinflammation in neurodegenerative pathogenesis (Barcia et al., 2012; Desplats et al., 2009; Hirsch & Hunot, 2009; Ma et al., 2013 ) and contribute F I G U R E 3 The expression profiles of cytokines induced by A53T mutant or wild-type (WT) α-syn. (a, b) mRNA expressions of IL-1β and IFN-β were significantly upregulated, as shown with a p value (p < 0.05) between treatment groups, displaying two types of induction patterns, that is, positive dosage-effect correlation and negative time-effect correlation, with an atypical pattern for IFN-β. (c) IFN-γ mRNA expression was significantly downregulated, as shown with a p value (p < 0.05) between treatment groups, and its minimal level was detected at high concentration (8 or 20 μg/ml) and early time-point (3 or 12 hr). (d) Protein release profile of IFN-γ by ELISA, demonstrating that IFN-γ supernatant levels were significantly reduced at high concentrations (8 and 20 μg/ml) and early time-points (3 and 12 hr), as shown with a p value (p < 0.05) between control and treatment groups, with WT α-syn having more reduction amplitude than A53T mutant. (e) Western blotting analysis for IL-1β (75 kDa), IFN-γ (19 kDa) and β-actin (45 kDa), a representative of three experiments. The signal sizes were identified according to manufacturer's instruction, and β-actin was used as reference control. (f) Densitometric analysis (ImageJ software) of IL-1β for panel e. Expression level (grayscale) of IL-1β was significantly enhanced by A53T mutant α-syn at 3 hr, and then reduced at 12 and 24 hr, a similar pattern to its mRNA expression, as shown with a p value (p < 0.05) between control and treatment groups. However, at 8 and 20 μg/ml, IL-1β expression was significantly downregulated, a different pattern from its mRNA expression, which may be associated with a potential exhaustive release of IL-1β. (g) Densitometric analysis (ImageJ software) of IFN-γ for panel e. Expression level (grayscale) of IFN-γ was significantly reduced by A53T mutant α-syn at 0.5-20 μg/ml or early time-points (3 and 12 hr), a similar pattern to its mRNA expression, as shown with a p value (p < 0.05) between control and treatment groups. The above data are presented with scatter charts showing sample distribution, sample number (n), means (-), and p values (significant difference specified at p < 0.05, by ANOVA, Margin means or LSD). Dose treatment at 2 μg/ml (24 hr) is the same condition as time treatment at 24 hr (2 μg/ml). [Colour figure can be viewed at wileyonlinelibrary.com] | WANG et Al.
F I G U R E 4
Additive application of TLR2 and TLR4 antagonists. (a, b) TLR2 antagonist (CPT22, 5 μg/ml) significantly downregulated mRNA expression of TLR3 induced by A53T mutant α-syn (2 μg/ml, 24 hr), along with a compensatory upregulation of TLR2, but TLR4 antagonist (C34, 5 μg/ml) had no extra induction effect on TLR2 and TLR3. Each comparison was shown with a p value (p < 0.05) between treatment groups. (c, d) Both CPT22 and C34 significantly upregulated NF-κB mRNA expression induced by A53T mutant α-syn, with a p value (p < 0.05) between treatment groups, indicating an activation state of inflammatory pathway in α-syn induction. (e, f) In A53T mutant α-syn stimulation, IL-1β mRNA expression was significantly downregulated by CPT22 at 12 and 24 hr, but was significantly upregulated by C34 at 12 hr, indicating a functional difference between TLR2 and TLR4 in α-syn induction. The above data are presented with scatter charts showing sample distribution, sample number (n), means (-), and p values (significant difference specified at p < 0.05, by ANOVA, Margin means, or LSD). Dose treatment at 2 μg/ml (24 hr) is the same condition as time treatment at 24 hr (2 μg/ml). [Colour figure can be viewed at wileyonlinelibrary.com] to formation of inflammatory microenvironment responsible for adjacent neuronal damage. While research predominantly focuses on microglia involvement in synucleinopathies (Roodveldt et al., 2013) , however, α-syn-induced astrocyte activation is still not fully investigated or only supported by limited literature. For example, α-syn released from neuron is directly transferred to astrocytes by sequential exocytosis and endocytosis and induces inflammatory response (Lee et al., 2010) , and its mutated isoforms (A30P, E46K, and A53T) have more stimulation effect than WT α-syn in release of IL-6 and ICAM-1 and upregulation of mitogen-activated protein kinase (MAPK) pathway in astrocytes and astrocytoma cells (Klegeris et al., 2006) . Astrocyte activation degree in vivo is inversely proportional to distance to α-syn inclusions, along with widespread neuroinflammation in α-syn-injected forebrain . In astrocytoma cell culture, co-incubation of α-syn and IL-1β potentiates protein expression but not RNA expression of CXCL10 (a proinflammatory chemokine), highlighting the importance of α-syn in modulating inflammatory events in astroglia (Tousi, Buck, Curtis, & Davis, 2012) . In primary astrocytes, A53T mutant α-syn triggers neuroinflammatory response by upregulating expression of GFAP, cyclooxygenase-2 (COX-2) and inducible nitric oxide (NO) synthase (iNOS), and by increasing production of TNF-α and IL-1β (Yu et al., 2018) . This study, for the first time, reported in-depth characterization of astrocytemediated innate immune response induced by A53T mutant and WT α-syn, suggesting the importance of astrocyte activation in mediating neuroinflammation in synucleinopathies (Roodveldt et al., 2010) .
Toll-like receptors are known as a family of transmembrane proteins to recognize extracellular immunogenic molecules and directly trigger innate immune pathways, leading to subsequent inflammatory response (Kawai & Akira, 2010) . Although correlation of TLRs activation and α-syn stimulation has been described (Fellner et al., 2013) , whether TLRs mediate α-syn-induced astrocyte activation and innate inflammatory response is still uncertain. In microglia culture, misfolded α-syn (50 ng/ml, 24 hr) upregulates TLR2 and TLR3 expressions, with no effect on NF-κB and TNF-α (Béraud et al., 2011) , but in spinal cord injury, TLR2 rather than TLR3 or TLR4 mediates microglia activation by α-syn (Qiao et al., 2015) ; Application of specific TLR agonists Pam3Csk4 and single-stranded RNA40 in microglia confirms differential effects of cell surface TLR1/2 and intracellular TLR7 on α-syninduced innate immunity, indicating TLR stimulation affects α-syn-induced response (Roodveldt et al., 2013) ; In PD brain pathology in vivo, different α-syn aggregates trigger inflammatory response through activation of TLR2, suggesting an association of α-syn cytotoxicity with its intrinsic structure (Gustot et al., 2015) ; α-Syn released from neuron into extracellular space is tested as an endogenous agonist for TLR2 to activate microglia-mediated inflammatory response (Kim et al., 2013; Roodveldt et al., 2013) . In this study, we demonstrated that A53T mutant or WT α-syn-induced activation of TLRs 1-4 in a PDEC or NTEC pattern, and also observed the induction pattern difference between cell surface TLR2 and intracellular TLR3, reflecting a possible biological implication: under α-syn stimulation, TLR2 mediates extracellular inflammatory pathway, while TLR3 mediates intracellular inflammatory pathway via α-syn endocytosis (Watson et al., 2012) . Moreover, additive application of antagonists indicates that TLR2, TLR3, and TLR4 are differently involved in the α-syn-induced inflammatory process. Our result that blockage of α-syn stimulation by TLR2 antagonist downregulated TLR3 expression is also consistent with the data from transgenic mice and in vitro models, which demonstrates that inactivation of TLR2 increases clearance of neuronal α-syn by activation of autophagy and reduces intracellular accumulation of α-syn (a TLR3 stimulator), and vice versa (Kim et al., 2015) . Likewise, TLR4 knockout technique shows participation of TLR4 in activation of microglia and astrocytes induced by WT α-syn (0.7 μM, 72 hr), but with no influence on uptake of α-syn in astrocytes other than microglia (Fellner et al., 2013; Rannikko, Weber, & Kahle, 2015) , indicating lack of direct involvement of TLR4 in intracellular accumulation of α-syn linked to TLR3 activation, as observed in our study.
Nuclear factor-kappa B, a pleiotropic regulator of target genes controlling physiological function and pathological process of neurodegeneration, plays a critical role in inflammatory pathway activation and production of cytokines/ chemokines by glial cells (Lanzillotta et al., 2015) . Its family members such as Rel-A (p65), Rel-B, c-Rel, NF-κB1 (p50/ p105), and NF-κB2 (p52/p100) can interact to form a cardinal controller of multiple signal pathways and participate in brain programming of many disease processes. Association of α-syn with NF-κB activation has been demonstrated. For instance, in murine microglia (BV2), exposure of α-syn causes migration of NF-ĸB p65 to nucleus (Couch, AlvarezErviti, Sibson, Wood, & Anthony, 2011) , and however, this is not observed in TLR4 knockout astrocytes (Rannikko et al., 2015) . Likewise, Reynolds and colleagues have shown that exposure of aggregated and nitrated α-syn modestly increases expression of all NF-κB subunits in microglia with a peak at as early as 4 hr poststimulation (Reynolds et al., 2008) , a similar pattern to what we observed in primary murine astrocytes in this study. These data support our results that A53T mutant α-syn significantly upregulated NF-κB expression at its high dose (8 and 20 μg/ml) and early time-points (3 and 12 hr), indicating a potential role of NF-κB pathway activation in α-syn induction of astrocyte-mediated neuroinflammation.
Proinflammatory cytokines are deleterious effectors of inflammatory response, determining immune activation status and cytotoxic outcomes. This process involves a range of pro-inflammatory and cytotoxic molecules such as
TNF-α, IL-6, IL-1β, superoxide, nitric oxide, reactive oxygen species and excitatory amino acids, and several antiinflammatory cytokines such as IL-10, IL-13, IL-14, and transforming growth factor-β (Kettenmann, Hanisch, Noda, & Verkhratsky, 2011; Vieira, Radford, Chung, Guillemin, & Pountney, 2015) . Accumulation of α-syn is a core feature of PD brain and leads to microglia and astrocyte activation and inflammatory cytokine/chemokine production. For example, in mouse microglia (BV-2), conditioned medium from SH-SY5Y cells over-expressing A53T mutant or WT α-syn, induces transcription and release of pro-inflammatory cytokines (Alvarez-Erviti, Couch, Richardson, Cooper, & Wood, 2011) . In α-syn endocytosis study in astrocytes, intracellular α-syn induces gene expression profile of pro-inflammatory cytokines and chemokines such as CXCL10, CCL2, and IL-6, which is correlated with the extent of α-syn accumulation (Farina et al., 2007) . Similar to our results in western blot analysis, A53T mutant or WT α-syn (1-5 μg/ml, 20 hr) does not induce production of TNF-α, IL-1β, and IFN-γ in primary glial cell culture by ELISA (Roodveldt et al., 2010) . Importantly, in α-syn-transgenic mouse model, mRNA expressions of cytokines such as TNF-α, IL-1β, and IL-6 are upregulated at 1, 6, and 12 months, with maximal expression at 1 month which subsequently reduces to the minimal at 12 months (Su, Federoff, & Maguire-Zeiss, 2009 ), a temporal pattern with much longer time intervals similar to the NTEC observed in our study. In addition, we also identified the pattern of PDEC in α-syn-induced mRNA expression of IL-1β, IFN-β, and TNF-α (similar data not shown). These temporal and dose induction patterns suggest that persistent release and accumulation of α-syn might be required for initiation and maintenance of inflammatory response in the synucleinopathy .
Moreover, we are the first to confirm the dose-related inhibitory effect of α-syn (A53T mutant or WT) on IFN-γ expression and production in primary murine astrocytes. This unexpected finding deserves further discussion and explanation: (a) We simultaneously observed upregulation of IFN-β, a cousin molecule of IFN-γ in innate immunity, providing a positive control. This result may also suggest differential roles of IFN-γ and IFN-β in α-syn-induced astrocyte activation; (b) A spatio-temporal differential distribution of IFN-γ expression has been observed in the brain. For example, a mutually exclusive distribution of α-syn and IFN-γ, that is, their strong negative correlation, is observed in the healthy substantia nigra, whereas in the PD substantia nigra, their coexpression or positive correlation is only detected (Liscovitch & French, 2014) . Likewise, IFN-γ high expression is mainly distributed in microglia from PD monkey substantia nigra, whereas TNF-α is highly expressed in astrocytes but not in microglia (Barcia et al., 2012) ; (c) The negative association between IFN-γ and other cytokines has also been demonstrated: co-exposure of IFN-γ with IL-1β or TNF-α leads to an inhibitory effect of IL-1β on IFN-γ expression in astrocytes and production of nitric oxide in microglia (Tichauer, Saud, & von Bernhardi, 2007) ; and (d) IFN-γ, primarily as a Th1-type proinflammatory cytokine, has also been shown to possess anti-inflammatory property at least in transgenic mouse model of experimental autoimmune encephalomyelitis (Mangalam et al., 2014) . Possibly in a highly inflammatory environment of synucleinopathy, IFN-γ could play an anti-inflammatory role, and by suppressing its expression, α-syn and its A53T mutant could further promote neuroinflammation. Together, the immune mechanism by which α-syn induces astrocyte activation and subsequent neuroinflammation is likely complex and our observation may provide an evidence for a novel immune molecule interaction mode that deserves further investigation.
| CONCLUSIONS
As shown in Graphical Abstract Figure (Kawai & Akira, 2010) , our data collectively confirm that A53T mutant or WT α-syn upregulated mRNA expression of the canonical inflammatory pathway components such as TLRs 1-4, NF-κB, and cytokines IL-1β, IFN-β. Our in-depth analyses showed two types of induction patterns, that is, PDEC and NTEC and a possible receptor interaction between TLR2 and TLR3 by antagonizing TLR2 and TLR4. In this process, however, IFN-γ expression was significantly downregulated at mRNA, protein, or protein release level, indicating a complex interaction of these inflammatory molecules. Therefore, we conclude that α-syn activates astrocyte-mediated innate immunity, suppresses IFN-γ expression and shows its immunogenic attribution, with A53T mutant having a stronger induction effect than WT α-syn. These findings may unravel a potential neurotoxic mechanism in synucleinopathies: A persistent release and accumulation of α-syn is required for maintenance of innate immunity activation, and cell typedominant expression of α-syn, IFN-γ, IL-1β, and TNF-α and their interaction in extracellular space might provide a novel immunological mechanism underlying inflammatory pathogenesis of neurodegenerative diseases.
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